| Cat. No. |
Product Name |
Information |
| PC-25191 |
Rovadicitinib
JAK/ROCK inhibitor
|
Rovadicitinib (TQ05105) is a potent, oral dual JAK1/2 and ROCK1/2 inhibitor targeting inflammatory and fibrotic components of chronic graft-versus-host disease (cGVHD). |
| PC-25103 |
Voderdeucitinib
TYK2 inhibitor
|
Voderdeucitinib is a potent selective TYK2 inhibitor. |
| PC-25095 |
Soficitinib
TYK2 inhibitor
|
Soficitinib is a potent, selective tyrosine kinase 2 (TYK2) inhibitor. |
| PC-25094 |
Socrodeucitinib
TYK2 inhibitor
|
Socrodeucitinib is a potent, selective TYK2 inhibitor. |
| PC-25084 |
Quecitinib
JAK1/TYK2 inhibitor
|
Quecitinib is a potent, selective dual JAK1/TYK2 inhibitor. |
| PC-25063 |
ESK-001 hydrochloride
TYK2 inhibitor
|
ESK-001 hydrochloride (Envudeucitinib) is a novel allosteric, highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) with IC50 of 104-149 nM in human whole blood, binds to JH2 domain of TYK2. |
| PC-25062 |
ESK-001
TYK2 inhibitor
|
ESK-001 (Envudeucitinib) is a novel allosteric, highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) with IC50 of 104-149 nM in human whole blood, binds to JH2 domain of TYK2. |
| PC-25034 |
TUL01101
JAK1 inhibitor
|
Blovacitinib (TUL01101) is a potent, selective and oral Janus kinase 1 (JAK1) inhibitor with IC50 of 3 nM, >12-fold selectivity for JAK2 and TYK2. |
| PC-24937 |
Cenacitinib
TYK2 inhibitor
|
Cenacitinib (VTX 958) is a potent, highly selective, allosteric and orally bioavailable inhibitor of tyrosine kinase 2 (TYK2). |
| PC-24735 |
NMS-P953
JAK2 inhibitor
|
NMS-P953 is a potent and selective JAK2 inhibitor with IC50 of 8 nM, displays 18-, 4- and 18-fold selective over JAK1, JAK3 and TYK2 respectively. |
| PC-24348 |
cTYK2i Compound-A
TYK2 inhibitor
|
cTYK2i Compound-A (Cmpd-A) is a potent, specific and brain-penetrant TYK2 inhibitor (cTYK2i) with IC50 of 6.4 nM. |
| PC-24191 |
Tofacitinib etocomil
JAK inhibitor
|
Tofacitinib etocomil (MH004) is a is a topical product containing a JAK inhibitor tofacitinib, shows extensive target inhibition in local skin tissues without systemic toxicities, has potential for multiple dermatologic autoimmune diseases. |
